Document:

Stock Purchase Warrant - Starfish LLC

 Exhibit 4.10 

NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR ANY STATE SECURITIES LAWS. NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY BE TRANSFERRED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE
SECURITIES LAWS, OR (B) IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS. 
  

			
	 Warrant Issue Date: March 6, 2008
	  	
                         
   Warrant No. 1-1

 STOCK PURCHASE WARRANT 

For value received, Amyris Biotechnologies, Inc. (the “Company”), a California corporation,
hereby certifies that Starfish, LLC (the “Holder”) or its permitted assign(s) is entitled to purchase from the Company, at any time or from time to time during the Exercise Period (as defined below), in whole or in part,
2,580 shares of Warrant Stock (as defined below) of the Company at the Exercise Price (as defined below). This Warrant is subject to the following terms and conditions. 

1.      Certain Definitions. 

(a)        “Change in Control” means (i) any sale,
lease, or other disposition of all or substantially all of the assets of the Company or (ii) any consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in
which the shareholders of the Company immediately prior to such consolidation, merger or reorganization, do not hold at least a majority of the resulting or surviving entity’s voting power immediately after such consolidation, merger or
reorganization. 
 (b)        “Exercise Period”
means the period commencing on the Warrant Issue Date and ending on the date that is the earliest to occur of (x) 5:00 p.m. (prevailing local time at the principal executive office of the Company) on the fifth (5th) anniversary of the
Warrant Issue Date, (y) a Change in Control, or (z) the closing of an initial public offering of the Company’s common stock pursuant to a registration statement under the Securities Act of 1933, as amended (the “Securities
Act”); provided, however, that the Company shall provide written notice to the Holder of a Change in Control or such initial public offering not less than ten (10) business days prior to the occurrence of such event.

 (c)        “Exercise Price” means $24.88 per
share of Warrant Stock, subject to adjustment as provided herein. 

(d)        “Warrant Stock” means the Company’s
Series B Preferred Stock. 
  

 1 

 2.      Exercise of Warrant.

 (a)        The purchase rights represented by this Warrant are
exercisable by the Holder, in whole or in part, during the Exercise Period by the surrender of this Warrant, with the form of Subscription Agreement attached hereto as Annex A duly completed and executed by the Holder, to the Company at its
principal executive office, accompanied by payment in cash, in lawful money of the United States of America, including by certified or official bank check made payable to the order of the Company or by wire transfer of immediately available funds to
an account designated by the Company, of an amount equal to the Exercise Price multiplied by the number of shares of Warrant Stock being purchased pursuant to such exercise of the Warrant. 

(b)        If the fair market value of one share of Warrant Stock is greater
than the Exercise Price (at the date of calculation as set forth below), then in lieu of exercising this Warrant for cash, the Holder may elect to receive shares of Warrant Stock equal to the value of this Warrant (or any portion hereof) by
surrender of this Warrant (or such portion) during the Exercise Period at the principal office of the Company together with the properly completed Subscription Agreement and notice of such election in which event the Company shall issue to the
Holder such number of shares of Warrant Stock computed using the following formula: 
 X = Y (A-B) 

    A 
 Where
X =      the number of shares of Warrant Stock to be issued to the Holder 
 Y
=      the number of shares of Warrant Stock purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being exercised 

A =      The fair market value of one share of the Company’s Warrant Stock (at the date of such exercise) 

B =      Exercise Price (as adjusted to the date of such exercise) 

For purposes of the above calculation, the fair market value of one share of Warrant Stock shall be the fair value as determined in good
faith by the Company’s Board of Directors or a duly appointed committee of the Board; provided, however, that in the event that the Warrant is being exercised in connection with the Company’s initial public offering, the fair
market value per share shall be the per share offering price of the Company’s initial public offering. 

(c)        This Warrant may be exercised for less than the full number of shares
of Warrant Stock first shown above, provided that this Warrant may not be exercised in part for less than a whole number of shares of Warrant Stock. Upon any such partial exercise, the Company at its expense will forthwith issue to the
Holder a new Warrant or Warrants of like tenor exercisable for the number of shares of Warrant Stock as to which rights have not been exercised (subject to adjustment as herein provided). 

(d)        As soon as practicable after the exercise of this Warrant and payment
of the aggregate Exercise Price, and in any event within 20 business days thereafter, the Company, at its expense, will cause to be issued in the name of and delivered to the Holder a certificate or

  

 2 

 
certificates for the number of duly authorized, validly issued, fully paid and non-assessable shares of Warrant Stock to which the Holder shall be entitled upon such exercise, plus, in lieu of
any fractional share to which the Holder would otherwise be entitled, cash in an amount determined in accordance with Section 3(d) hereof. The Company agrees that the shares so purchased shall be deemed to be issued to the Holder as the
record owner of such shares as of the close of business on the date on which this Warrant shall have been exercised. 

(e)        Prior to the exercise of this Warrant, the Holder shall not be
entitled to any rights of a shareholder of the Company with respect to shares for which this Warrant shall be exercisable, including, without limitation, the right to vote, to receive dividends or other distributions or to exercise any preemptive
rights, and shall not be entitled to receive any notice of any proceedings of the Company. 

3.      Adjustments. 

(a)        Adjustments Generally. In order to prevent dilution of the
rights granted hereunder in the specific circumstances contemplated by this Section 3, the number of shares of Warrant Stock underlying this Warrant and the Exercise Price shall be subject to adjustment from time to time in accordance herewith.
Upon each adjustment of the Exercise Price pursuant to this Section 3, the Holder shall thereafter be entitled to acquire upon exercise, at the Exercise Price resulting from such adjustment, the number of shares of the Company’s Warrant
Stock determined by (i) multiplying (A) the Exercise Price in effect immediately prior to such adjustment by (B) the number of shares of Warrant Stock issuable upon exercise hereof immediately prior to such adjustment, and
(ii) dividing the product thereof by the Exercise Price resulting from such adjustment. 

(b)        Subdivisions and Combinations. In case the Company shall at
any time subdivide its outstanding shares of Warrant Stock into a greater number of shares (including, without limitation, through any stock split effected by means of a dividend on the Warrant Stock which is payable in Warrant Stock), the Exercise
Price in effect immediately prior to such subdivision shall be proportionately reduced, and, conversely, in case the outstanding shares of Warrant Stock of the Company shall be combined into a smaller number of shares, the Exercise Price in effect
immediately prior to such combination shall be proportionately increased. 

(c)        Reorganization, Reclassification, Consolidation, Merger or Sale of
Assets. If, at any time prior to the exercise of this Warrant in full, the Company shall (i) effect any capital reorganization or reclassification of the capital stock of the Company, or consolidate or merge the Company with another entity,
or sell, lease, or otherwise dispose of a significant amount of assets, in any such case in such a way that does not constitute a Change in Control, (ii) declare a dividend or make a distribution on the Warrant Stock payable in shares of its
capital stock of any class, securities, cash or other property; or (iii) issue any shares of its capital stock by reclassification of its Warrant Shares (including any such reclassification in connection with a consolidation or a merger in
which the Company is the continuing corporation), then, as a condition of such reorganization, reclassification, consolidation, merger or sale, lawful and adequate provision shall be made whereby the Holder shall have the right to acquire and
receive upon exercise of this Warrant in accordance with the terms hereof such shares of stock, securities, cash or other property of the successor entity that a holder of the shares deliverable

  

 3 

 
upon exercise of this Warrant would have been entitled to receive in such reorganization, reclassification, consolidation, merger or sale if this Warrant had been exercised immediately before
such reorganization, reclassification, consolidation, merger or sale. The foregoing provisions shall similarly apply to successive reorganizations, reclassifications, consolidations, mergers or sales and to the stock or securities of any other
corporation that are at the time receivable upon the exercise of this Warrant. In all events, appropriate adjustments (as determined by the Board of Directors of the Company) shall be made in the application of the provisions of this Warrant with
respect to the rights and interests of the Holder after the transaction, to the end that the provisions of this Warrant shall be applicable after that event, as near as reasonably may be, in relation to any shares or other property deliverable after
that event upon exercise of this Warrant. 
 (d)        Fractional
Shares. The Company shall not issue fractions of shares of Warrant Stock upon exercise of this Warrant or scrip in lieu thereof. If any fraction of a share of Warrant Stock would, except for the provisions of this Section 3(d), be issuable
upon exercise of this Warrant, then the Company shall in lieu thereof pay to the person entitled thereto an amount in cash equal to the current value of such fraction, calculated to the nearest one-hundredth (1/100) of a share, to be computed
on the basis of the fair market value per share as determined by the Board of Directors of the Company in accordance with the provisions of Section 2(b). 

(e)        Certificate as to Adjustments. Whenever the Exercise Price
shall be adjusted as provided in Section 3 hereof the Company shall promptly compute such adjustment and furnish to the Holder a certificate setting forth such adjustment and showing in reasonable detail the facts requiring such adjustment, the
Exercise Price that will be effective after such adjustment and the number of shares and the amount, if any, of other property that at the time would be received upon the exercise of this Warrant. 

4.      Reservation of Stock Issuable on Exercise of Warrant. The Company shall at
all times reserve and keep available out of its authorized but unissued stock, solely for the issuance and delivery upon the exercise of this Warrant, such number of its duly authorized shares of Warrant Stock as from time to time shall be issuable
upon the exercise of this Warrant. All of the shares of Warrant Stock issuable upon exercise of this Warrant, when issued and delivered in accordance with the terms hereof and thereof, will be duly authorized, validly issued, fully paid and
non-assessable, subject to no lien or other encumbrance other than restrictions on transfer arising under applicable securities laws and restrictions imposed by Section 6(a) hereof and the Agreements to which reference is made in
Section 6(b) hereof. 
 5.      Replacement of Warrant. Upon
receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement reasonably satisfactory to the Company
(with surety if reasonably required), or (ill the case of mutilation) upon surrender and cancellation thereof, the Company will issue, in lieu thereof, a new Warrant of like tenor and amount. 

6.      Negotiability. This Warrant is issued upon the following terms: 

(a)        Transfer. By acceptance hereof, the Holder acknowledges and
agrees that, except upon the prior written consent of the Company, this Warrant may not be transferred, and 
  

 4 

 
this Warrant may be exercised only by the Holder. Holder is acquiring the Warrant and the shares of Warrant Stock issuable upon exercise hereof for investment for its own account, not as a
nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof, and Holder has no present intention of selling, granting any participation in, or otherwise distributing the same. 

(b)        Agreements. As a condition to the Company’s obligation to
issue shares of capital stock upon exercise hereof the Holder shall execute the Subscription Agreement attached hereto as Annex A and such stock transfer restriction and voting agreements as may reasonably be requested by the Company.

 (c)        Transfer Taxes. The Company shall not be required
to pay any federal or state transfer tax or charge that may be payable in respect of any transfer involved in the transfer or delivery of this Warrant or the issuance or delivery of certificates for Warrant Stock in a name other than that of the
Holder or to issue or deliver any certificates for Warrant Stock upon the exercise of this Warrant until any and all such taxes and charges shall have been paid by the Holder or until it has been established to the Company’s reasonable
satisfaction that no such tax or charge is due. 

(d)        Compliance with Securities Laws. The Holder, by acceptance
hereof, acknowledges that this Warrant and the shares of Warrant Stock to be issued upon exercise hereof are being acquired solely for the Holder’s own account and not as a nominee for any other party, and for investment, and that the Holder
will not offer, sell or otherwise dispose of this Warrant or any shares of Warrant Stock to be issued upon exercise hereof except under circumstances that will not result in a violation of applicable federal and state securities laws. 

7.      Subdivision of Rights. Subject to Section 6, this Warrant (as well as
any new Warrants issued pursuant to the provisions of this Section 7) is exchangeable, upon the surrender hereof by the Holder, at the principal executive office of the Company for any number of new Warrants of like tenor and date representing
in the aggregate the right to subscribe for and purchase the number of shares of Warrant Stock of the Company which may be subscribed for mid purchased hereunder. 

8.      No Impairment. The Company shall not by any action including, without
limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such commercially reasonable actions as may be necessary or appropriate to protect the rights
of Holder against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares receivable upon the exercise of this Warrant above the amount payable therefor upon such
exercise immediately prior to such increase in par value, (b) take all such commercially reasonable action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant, and (c) use its commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company
to perform its obligations under this Warrant. 
  

 5 

 9.      Miscellaneous. 

(a)        Notices. Any notice or other communication required or
permitted to be given hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient,
if not, then on the next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) the next business day after deposit with a nationally recognized overnight
courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company and to the Holder at the address or facsimile number set forth on such party’s signature page hereof or at such other
address as the Company or the Holder may designate by 10 days’ advance written notice to the other parties hereto. 

(b)        Books of the Company. The Company may treat the holder hereof
as appearing on the Company’s books at any time as the holder for all purposes. 

(c)        Headings. The headings in this Warrant are for purposes of
reference only, and shall not limit or otherwise affect the meaning hereof. 

(d)        Amendment Waiver. This Warrant and any term hereof may be
amended, waived, discharged or terminated only by an instrument in writing signed by the party against whom enforcement of such amendment, waiver, discharge or termination is sought. No waivers of any term, condition or provision of this Warrant, in
any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision. 

(e)        Benefits of this Warrant. Nothing in this Warrant shall be
construed to give any person or corporation other than the Company and the Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be for the sole and exclusive benefit of the Company and the Holder and any
other permitted holder or holders of the Warrant. 

(f)        Successor and Assigns. Subject to compliance with the
provisions of Section 6(a), this Warrant and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and assigns of Holder. The provisions of this Warrant are intended to be
for the benefit of all Holders from time to time of this Warrant, and shall be enforceable by any such Holder. 

(g)        Severability. Wherever possible, each provision of this
Warrant shall be interpreted in such manner as to be effective and valid tinder applicable law, but if any provision of this Warrant shall be prohibited by or invalid tinder applicable law, such provision shall be modified to the extent of such
prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Warrant. 

(h)        Headings. The headings used in this Warrant are for the
convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. 
  

 6 

 (i)        Governing Law.
This Warrant and the transactions contemplated hereby shall be governed by and interpreted in accordance with the local laws of the State of California without regard to the provisions thereof relating to conflicts of laws. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 7 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed
and delivered by its authorized officer, as of the date first above written. 
  

			
	 AMYRIS BIOTECHNOLOGIES, INC.

		
	 By:
	 	 /s/ Tamara L.
Tompkins

			
	 Name:
	 	  Tamara L.
Tompkins

			
	 Title:
	 	  General Counsel

 

	
	 AGREED TO AND ACCEPTED:

	
	 HOLDER

	 STARFISH, LLC

	
	  /s/ [signature illegible]

 

 8 

 ANNEX A 

SUBSCRIPTION AGREEMENT 
 Date:
                                         
        
  

	To:	 Amyris Biotechnologies, Inc. 

5980 Horton Street, Suite 350 

Emeryville, CA 94608 

The undersigned (the “Purchaser”), pursuant to the provisions set forth in the attached Warrant,
hereby irrevocably elects (check and complete appropriate box): 
  ̈
 to purchase              shares of Warrant Stock (the “Warrant Shares”) covered by such Warrant and herewith makes payment of
$            , representing the full purchase price for such shares at the price per share provided for in such Warrant. 

 ̈ to exercise the Warrant with respect to
             shares of Warrant Stock, pursuant to Section 2(b) of the Warrant. 

Purchaser represents and warrants to the Company as follows: 

1.      Investment Representations. Purchaser understands that the Warrant Shares have not been
registered under the Securities Act. Purchaser also understands that the Warrant Shares are being offered and sold pursuant to an exemption from registration contained in the Securities Act based in part upon Purchaser’s representations
contained herein. 
 2.      Experience; Risk. Purchaser has such knowledge and experience
in financial and business matters that Purchaser is capable of evaluating the merits and risks of the purchase of the Warrant Shares and of protecting Purchaser’s interests in connection therewith. Purchaser is able to fend for itself in the
transactions contemplated by this Agreement and has the ability to bear the economic risk of the investment, including complete loss of the investment. 

3.      Investment. Purchaser is acquiring the Warrant Shares for investment for its own account,
not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof, and Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. Purchaser
understands that the Warrant Shares have not been registered under the Securities Act and applicable state securities laws (collectively, the “Acts”) by reason of a specific exemption from the registration provisions of the Acts which
depends upon, among other things, the bona fide nature of the investment intent and the accuracy of Purchaser’s representations as expressed herein. 

4.      Information. Purchaser has been furnished with all information which it deems necessary to
evaluate the merits and risks of purchasing the Warrant Shares and has had the opportunity to ask questions concerning the Warrant Shares and the Company and all questions posed have been answered to its satisfaction. Purchaser has been given the
opportunity to obtain any additional information it deems necessary to verify the accuracy of any information obtained 

 
concerning the Warrant Shares and the Company. Purchaser has such knowledge and experience in financial and business matters that it is able to evaluate the merits and risks of purchasing the
Warrant Shares and to make an informed decision relating thereto. 
 5.      Restricted
Securities; Restrictions on Transfer. Purchaser understands that the Warrant Shares will be “restricted securities” under applicable securities laws inasmuch as they are being acquired from the Company in a transaction not involving a
public offering and that under such laws and applicable regulations the Warrant Shares may be resold without registration under the Acts only in certain limited circumstances. Purchaser acknowledges that the Warrant Shares must be held indefinitely
unless subsequently registered under the Acts or an exemption from such registration is available. Purchaser agrees to execute and deliver a counterpart signature page, and become a party, to such agreements as other purchasers of Warrant Stock are
a party to and such other stock transfer restriction, voting and other agreements as may be requested by the Company. 

6.      No Public Market. Purchaser understands that no public market now exists for any of the
securities issued by the Company and that there is no assurance that a public market will ever exist for such securities. 

7.      Accredited Investor. Purchaser is an “accredited investor” within the meaning of
Rule 501 promulgated under the Securities Act. The Purchaser has considered the Federal and state income tax implications of the exercise of the Warrant and the purchase and subsequent sale of the Warrant Shares. 

8.      Residence. If Purchaser is an individual, then Purchaser resides in the state or province
identified in the address of Purchaser set forth below; if Purchaser is a partnership, corporation, limited liability company or other entity, then the office or offices of Purchaser in which its investment decision was made is located at the
address or addresses of Purchaser set forth below. 
 9.      Further Limitations on
Disposition. Without in any way limiting the representations set forth above, Purchaser further agrees not to make any disposition of any Shares unless and until: 

(i)      there is then in effect a registration statement under the Acts covering such
proposed disposition and such disposition is made in accordance with such registration statement; or 

(ii)      Purchaser shall have notified the Company of the proposed disposition, and shall
have furnished the Company with a statement of the circumstances surrounding the proposed disposition, and, at the expense of Purchaser or its transferee, with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will
not require registration of such securities under any of the Acts. 
 10.      Legends.
Purchaser understands and agrees that any certificate or other instrument representing the Shares will bear a legend substantially similar to the legend set forth below: 

THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR ANY STATE SECURITIES LAWS. NEITHER THIS SECURITY NOR THE 
  

 2 

 
SECURITIES ISSUABLE UPON CONVERSION [EXERCISE] HEREOF MAY BE TRANSFERRED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION UNDER TILE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE
SECURITIES LAWS, OR (B) IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS. 

The legend set forth above shall be removed by the Company from any certificate or other instrument representing the Shares upon delivery
to the Company of an opinion of counsel reasonably satisfactory to the Company that a registration statement under the Securities Act is at that time in effect with respect to the legended security or that such security can be freely transferred in
a public sale without such a registration statement being in effect and that such transfer will not jeopardize the exemption or exemptions from registration pursuant to which the Company issued the Shares. 

 

	
	  

	 Signature

	
	  

	 Print name:

	
	 Address:

	
	  

	  

	  

 

 3 

 NOTICE OF TRANSFER 

[To be signed only upon transfer of Warrant] 

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto the Assignee named below the rights and obligations
represented by the within Warrant with respect to the number of shares of Warrant Stock of              set forth below: 

 

					
	 Name of Assignee
	 	Address	 	No. of Shares
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	

 and appoints
                                 attorney to transfer said right on the warrant register
of                  with full power of substitution in the premises. 
  

							
	 Dated:
	 	  
	 		 	  

		 		 		 	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)
				
		 		 		 	 Address:

				
		 		 		 	  

		 		 		 	  

		 		 		 	  

 Attachment B 

Form of Warrant 

 NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY BE TRANSFERRED EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS. 

 

			
	Warrant Issue Date: January 2008	 	Warrant No. 1-1            

STOCK PURCHASE WARRANT 

For value received, Amyris Biotechnologies, Inc. (the “Company”), a California corporation,
hereby certifies that Starfish, LLC (the “Holder”) or its permitted assign(s) is entitled to purchase from the Company, at any time or from time to time during the Exercise Period (as defined below), in whole or in part,
2,580 shares of Warrant Stock (as defined below) of the Company at the Exercise Price (as defined below). This Warrant is subject to the following terms and conditions. 

 

	 	1.	 Certain Definitions. 

(a)        “Change in Control” means (i) any sale,
lease, or other disposition of all or substantially all of the assets of the Company or (ii) any consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in
which the shareholders or the Company immediately prior to such consolidation, merger or reorganization, do not hold at least a majority of the resulting or surviving entity’s voting power immediately after such consolidation, merger or
reorganization. 
 (b)        “Exercise Period”
means the period commencing on the Warrant Issue Date and ending on the date that is the earliest to occur of (x) 5:00 p.m. (prevailing local time at the principal executive office of the Company) on the fifth (5th) anniversary of the
Warrant Issue Date, (y) a Change in Control, or (z) the closing of an initial public offering of the Company’s common stock pursuant to a registration statement under the Securities Act of 1933, as amended (the “Securities
Act”); provided, however, that the Company shall provide written notice to the Holder of a Change in Control or such initial public offering not less than ten (10) business days prior to the occurrence or such event.

 (c)        “Exercise Price” means $24.88 per
share of Warrant Stock, subject to adjustment as provided herein. 

(d)        “Warrant Stock” means the Company’s
Series B Preferred Stock. 
  

	 	2.	 Exercise of Warrant. 

(a)          The purchase rights represented by this Warrant are
exercisable by the Holder, in whole or in part, during the Exercise Period by the surrender of this Warrant, with the 

 
form of Subscription Agreement attached hereto as Annex A duly completed and executed by the Holder, to the Company at its principal executive office, accompanied by payment in cash, in lawful
money of the United States of America, including by certified or official bank check made payable to the order of the Company or by wire transfer of immediately available funds to an account designated by the Company, of an amount equal to the
Exercise Price multiplied by the number of shares of Warrant Stock being purchased pursuant to such exercise of the Warrant. 

(b)        If the fair market value of one share of Warrant Stock is greater
than the Exercise Price (at the date of calculation as set forth below), then in lieu of exercising this Warrant for cash, the Holder may elect to receive shares of Warrant Stock equal to the value of this Warrant (or any portion hereof) by
surrender of this Warrant (or such portion) during the Exercise Period at the principal office of the Company together with the properly completed Subscription Agreement and notice of such election in which event the Company shall issue to the
Holder such number of shares of Warrant Stock computed using the following formula: 
 X = Y (A-B) 

  A 
 Where X
=      the number of shares of Warrant Stock to be issued to the Holder 
 Y
=      the number of shares of Warrant Stock purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being exercised 

A =      The fair market value of one share of the Company’s Warrant Stock (at the date of such exercise) 

B = Exercise Price (as adjusted to the date of such exercise) 

For purposes of the above calculation, the fair market value of one share of Warrant Stock shall be the fair value as determined in good
faith by the Company’s Board of Directors or a duly appointed committee of the Board; provided, however, that in the event that the Warrant is being exercised in connection with the Company’s initial public offering, the fair
market value per share shall be the per share offering price of the Company’s initial public offering. 

(c)        This Warrant may be exercised for less than the full number of shares
of Warrant Stock first shown above, provided that this Warrant may not be exercised in part for less than a whole number of shares of Warrant Stock. Upon any such partial exercise, the Company at its expense will forthwith issue to the
Holder a new Warrant or Warrants of like tenor exercisable for the number of shares of Warrant Stock as to which rights have not been exercised (subject to adjustment as herein provided). 

(d)        As soon as practicable after the exercise of this Warrant and payment
of the aggregate Exercise Price, and in any event within 20 business days thereafter, the Company, at its expense, will cause to be issued in the name of and delivered to the Holder a certificate or certificates for the number of duly authorized,
validly issued, fully paid and non-assessable shares of Warrant Stock to which the Holder shall be entitled upon such exercise, plus, in lieu of any fractional share to which the Holder would otherwise be entitled, cash in an amount determined in
accordance with Section 3(d) hereof. The Company agrees that the shares so 
  

 2 

 
purchased shall be deemed to be issued to the Holder as the record owner of such shares as of the close of business on the date on which this Warrant shall have been exercised. 

(e)        Prior to the exercise of this Warrant, the Holder shall not be
entitled to any rights of a shareholder of the Company with respect to shares for which this Warrant shall be exercisable, including, without limitation, the right to vote, to receive dividends or other distributions or to exercise any preemptive
rights, and shall not be entitled to receive any notice of any proceedings of the Company. 
  

	 	3.	 Adjustments. 

(a)        Adjustments Generally. In order to prevent dilution of the
rights granted hereunder in the specific circumstances contemplated by this Section 3, the number of shares of Warrant Stock underlying this Warrant and the Exercise Price shall be subject to adjustment from time to time in accordance herewith.
Upon each adjustment of the Exercise Price pursuant to this Section 3, the Holder shall thereafter be entitled to acquire upon exercise, at the Exercise Price resulting from such adjustment, the number of shares of the Company’s Warrant
Stock determined by (i) multiplying (A) the Exercise Price in effect immediately prior to such adjustment by (B) the number of shares of Warrant Stock issuable upon exercise hereof immediately prior to such adjustment, and
(ii) dividing the product thereof by the Exercise Price resulting from such adjustment. 

(b)        Subdivisions and Combinations. In case the Company shall at
any time subdivide its outstanding shares of Warrant Stock into a greater number of shares (including, without limitation, through any stock split effected by means of a dividend on the Warrant Stock which is payable in Warrant Stock), the Exercise
Price in effect immediately prior to such subdivision shall be proportionately reduced, and, conversely, in case the outstanding shares of Warrant Stock of the Company shall be combined into a smaller number of shares, the Exercise Price in effect
immediately prior to such combination shall be proportionately increased. 

(c)        Reorganization, Reclassification, Consolidation, Merger or Sale of
Assets. If, at any time prior to the exercise of this Warrant in full, the Company shall (i) effect any capital reorganization or reclassification of the capital stock of the Company, or consolidate or merge the Company with another entity,
or sell, lease, or otherwise dispose of a significant amount of assets, in any such case in such a way that does not constitute a Change in Control, (ii) declare a dividend or make a distribution on the Warrant Stock payable in shares of its
capital stock of any class, securities, cash or other property; or (iii) issue any shares of its capital stock by reclassification of its Warrant Shares (including any such reclassification in connection with a consolidation or a merger in
which the Company is the continuing corporation), then, as a condition of such reorganization, reclassification, consolidation, merger or sale, lawful and adequate provision shall be made whereby the Holder shall have the right to acquire and
receive upon exercise of this Warrant in accordance with the terms hereof such shares of stock, securities, cash or other property of the successor entity that a holder of the shares deliverable upon exercise of this Warrant would have been entitled
to receive in such reorganization, reclassification, consolidation, merger or sale if this Warrant had been exercised immediately before such reorganization, reclassification, consolidation, merger or sale. The foregoing provisions shall similarly
apply to successive reorganizations, reclassifications, consolidations, 
  

 3 

 
mergers or sales and to the stock or securities of any other corporation that are at the time receivable upon the exercise of this Warrant. In all events, appropriate adjustments (as determined
by the Board of Directors of the Company) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder after the transaction, to the end that the provisions of this Warrant shall be
applicable after that event, as near as reasonably may be, in relation to any shares or other property deliverable after that event upon exercise of this Warrant. 

(d)        Fractional Shares. The Company shall not issue fractions of
shares of Warrant Stock upon exercise of this Warrant or scrip in lieu thereof. If any fraction of a share of Warrant Stock would, except for the provisions of this Section 3(d), be issuable upon exercise of this Warrant, then the Company shall
in lieu thereof pay to the person entitled thereto an amount in cash equal to the current value of such fraction, calculated to the nearest one-hundredth (1/100) of a share, to be computed on the basis of the fair market value per share as
determined by the Board of Directors of the Company in accordance with the provisions of Section 2(b). 

(e)        Certificate as to Adjustments. Whenever the Exercise Price
shall be adjusted as provided in Section 3 hereof, the Company shall promptly compute such adjustment and furnish to the Holder a certificate setting forth such adjustment and showing in reasonable detail the facts requiring such adjustment,
the Exercise Price that will be effective after such adjustment and the number of shares and the amount, if any, of other property that at the time would be received upon the exercise of this Warrant. 

4.      Reservation of Stock Issuable on Exercise of Warrant. The Company shall at
all times reserve and keep available out of its authorized but unissued stock, solely for the issuance and delivery upon the exercise of this Warrant, such number of its duly authorized shares of Warrant Stock as from time to time shall be issuable
upon the exercise of this Warrant. All of the shares of Warrant Stock issuable upon exercise of this Warrant, when issued and delivered in accordance with the terms hereof and thereof, will be duly authorized, validly issued, fully paid and
non-assessable, subject to no lien or other encumbrance other than restrictions on transfer arising under applicable securities laws and restrictions imposed by Section 6(a) hereof and the Agreements to which reference is made in
Section 6(b) hereof. 
 5.      Replacement of Warrant. Upon
receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement reasonably satisfactory to the Company
(with surety if reasonably required), or (in the case of mutilation) upon surrender and cancellation thereof, the Company will issue, in lieu thereof, a new Warrant of like tenor and amount. 

6.      Negotiability. This Warrant is issued upon the following terms: 

(a)        Transfer. By acceptance hereof, the Holder acknowledges and
agrees that, except upon the prior written consent of the Company, this Warrant may not be transferred, and this Warrant may be exercised only by the Holder. Holder is acquiring the Warrant and the shares of Warrant Stock issuable upon exercise
hereof for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution 

 

 4 

 
thereof, and Holder has no present intention of selling, granting any participation in, or otherwise distributing the same. 

(b)        Agreements. As a condition to the Company’s obligation to
issue shares of capital stock upon exercise hereof, the Holder shall execute the Subscription Agreement attached hereto as Annex A and such stock transfer restriction and voting agreements as may reasonably be requested by the Company.

 (c)        Transfer Taxes.  The Company shall not
be required to pay any federal or state transfer tax or charge that may be payable in respect of any transfer involved in the transfer or delivery of this Warrant or the issuance or delivery of certificates for Warrant Stock in a name other than
that of the Holder or to issue or deliver any certificates for Warrant Stock upon the exercise of this Warrant until any and all such taxes and charges shall have been paid by the Holder or until it has been established to the Company’s
reasonable satisfaction that no such tax or charge is due. 

(d)        Compliance with Securities Laws. The Holder, by acceptance
hereof, acknowledges that this Warrant and the shares of Warrant Stock to be issued upon exercise hereof are being acquired solely for the Holder’s own account and not as a nominee for any other party, and for investment, and that the Holder
will not offer, sell or otherwise dispose of this Warrant or any shares of Warrant Stock to be issued upon exercise hereof except under circumstances that will not result in a violation of applicable federal and state securities laws. 

7.      Subdivision of Rights. Subject to Section 6, this Warrant (as well as
any new Warrants issued pursuant to the provisions of this Section 7) is exchangeable, upon the surrender hereof by the Holder, at the principal executive office of the Company for any number of new Warrants of like tenor and date representing
in the aggregate the right to subscribe for and purchase the number of shares of Warrant Stock of the Company which may be subscribed for and purchased hereunder. 

8.      No Impairment. The Company shall not by any action including, without
limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such commercially reasonable actions as may be necessary or appropriate to protect the rights
of Holder against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares receivable upon the exercise of this Warrant above the amount payable therefor upon such
exercise immediately prior to such increase in par value, (b) take all such commercially reasonable action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant, and (c) use its commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company
to perform its obligations under this Warrant. 
  

 5 

	 	9.	 Miscellaneous. 

(a)        Notices. Any notice or other communication required or
permitted to be given hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient,
if not, then on the next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) the next business day after deposit with a nationally recognized overnight
courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company and to the Holder at the address or facsimile number set forth on such party’s signature page hereof or at such other
address as the Company or the Holder may designate by 10 days’ advance written notice to the other parties hereto. 

(b)        Books of the Company. The Company may treat the holder hereof
as appearing on the Company’s books at any time as the holder for all purposes. 

(c)        Headings. The headings in this Warrant are for purposes of
reference only, and shall not limit or otherwise affect the meaning hereof. 

(d)        Amendment; Waiver. This Warrant and any term hereof may be
amended, waived, discharged or terminated only by an instrument in writing signed by the party against whom enforcement of such amendment, waiver, discharge or termination is sought. No waivers of any term, condition or provision of this Warrant, in
any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision. 

(e)        Benefits of this Warrant. Nothing in this Warrant shall be
construed to give any person or corporation other than the Company and the Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be for the sole and exclusive benefit of the Company and the Holder and any
other permitted holder or holders of the Warrant. 

(f)        Successor and Assigns. Subject to compliance with the
provisions of Section 6(a), this Warrant and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and assigns of Holder. The provisions of this Warrant are intended to be
for the benefit of all Holders from time to time of this Warrant, and shall be enforceable by any such Holder. 

(g)        Severability. Wherever possible, each provision of this
Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be modified to the extent of such
prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Warrant. 

(h)        Headings. The headings used in this Warrant are for the
convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. 
  

 6 

 (i)        Governing Law.
This Warrant and the transactions contemplated hereby shall be governed by and interpreted in accordance with the local laws of the State of California without regard to the provisions thereof relating to conflicts of laws. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 7 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed and delivered by
its authorized officer, as of the date first above written. 
  

			
	AMYRIS BIOTECHNOLOGIES, INC.
		
	 By:
	 	
 

			
	 Name:
	 	
 

			
	 Title:
	 	  

 

	
	 AGREED TO AND ACCEPTED:

	
	 HOLDER

	STARFISH, LLC
	
	  

 

 8 

 

 

 Statement of Work #1 

This Statement of Work #1 is entered into by and between Amyris Biotechnologies, Inc., (“Amyris”) and Starfish, LLC
(“Service Provider”) effective as of July 26, 2007 as a supplement to the Master Services Agreement dated July 26, 2007 by and between the parties (the “Services Agreement”). Pursuant to Section 1 of the Services
Agreement, this Statement of Work #1 shall set forth the terms and conditions under which Service Provider shall perform certain services for Amyris. All capitalized terms used herein and not otherwise defined shall have the meaning set forth in the
Services Agreement. 
  

	1.	 General Scope/Nature of Work 

Brand development. 
  

	2.	 Description of Services 

As set forth on Attachment A. 
  

	3.	 Term of SOW  

As set forth on Attachment A. 
  

	4.	 Deliverables  

As set forth on Attachment A. 
  

	5.	 Fees 

Fees in the amount of $192,500 plus a warrant in the form attached hereto as Attachment B. 

 

	6.	 Payments 

Service Provider shall submit to Amyris reasonably detailed invoices for all services rendered and expenses incurred at
the end of each month in which Service Provider provided Services. Within thirty (30) days of receipt of Service Provider’s invoice, payment will be made by Amyris for each hour in which Service Provider has satisfactorily provided
Services. 
  

	7.	 Expenses 

Amyris shall reimburse Service Provider for all travel expenses incurred in connection with this Agreement upon submission
and verification of customary receipts and vouchers. Unless otherwise agreed by Amyris in advance, all air travel shall be economy class. 

 IN WITNESS WHEREOF, and intending to be bound by the provisions hereof, the parties hereto
have caused this Statement of Work #1 to be executed personally or by their duly authorized representatives, to be effective as of the day and year set forth above. 
  

									
	 STARFISH, LLC
	 		 	 AMYRIS BIOTECHNOLOGIES, INC.

					
	 By:
	 	 /s/ David Kassler
	 		 	 By:
	 	 /s/ Tamara L. Tompkins

					
	 Name:
	 	   David Kassler
	 		 	 Name:
	 	 Tamara L. Tompkins

					
	 Title:
	 	   President
	 		 	 Title:
	 	 General Counsel

 

 2 

 Attachment A 

Phase One: 
 Audit and Diagnosis

 A full and rich articulation of the brand is critical to all future brand development. Starfish must determine what the brand stands for
going forward, how it will be differentiated and how it will be presented to the marketplace. In order to create the brand in an effective manner, a fair amount of homework will be required. 

Process 
  

	I.	Kick-off meeting. 

 Starfish will
meet with Amyris to refine the details of the process and specific deliverables. The parties will also, as a group, begin to share preliminary thoughts and insights that will guide us in our investigations moving forward. 

 

	II.	Brand Dig 

 a. Desk Research
(Category & Consumer analysis) 
 In this first working step, Starfish will review all relevant marketplace, competitive
and consumer information/ data in order to insure that Starfish can offer a comprehensive overview of the barriers and opportunities. 

b. Insight Gathering: 

For insight in how the brand will be perceived by the community at large Starfish will utilize a Multi-Constituent Perception Analysis and
conduct a thorough set of internal and external interviews. 
 Internally, Starfish will conduct executive interviews with
members of Amyris, senior management team, board members and key investors to gain a solid footing in core values, existing beliefs and attitudes about the company and brand. 

Clearly the distribution channel is a critically important part of Amyris’ business and therefore Starfish will spend a fair amount
of time analyzing this sector’s understanding of the biofuel category including their motivations and needs. Starfish believes this type of research should be accomplished in person and recommend visiting 10-15 different locations across the
country to gain a perspective on their attitudes and beliefs as well as their unique needs in terms of required support and training. This analysis will help us to understand the competitive dynamics and if there are any geographic variations in
behaviors. 
 Externally, Starfish will meet with 8-10 industry opinion leaders, magazine/newspaper editors, analysts or industry
insiders. 
 Also, Starfish will survey 30-50 customers across the different segments once they’re defined. These will take
the form of one-on-one interviews. The purpose of these interviews will be to elicit information, insight and guidance in establishing a 360o perspective of the brand and uncovering inconsistencies in stakeholder perceptions. 

Starfish will submit a questionnaire for Amyris’ approval before any research is conducted. 

 c. Competitive Analysis: 

Our competitive analysis can be divided into three sections: Positioning Analysis, Competitive Activity/Spending and Marketing
Communications Analysis and Marketplace Analysis. 
 In Positioning Starfish will outline Amyris’ key competitors’
brand positioning as expressed in their marketing communications, and map the results in order to uncover potential gaps that Starfish might exploit. To accomplish this Starfish will review as much of Amyris’ key competitors’ Marketing
Communications materials as Starfish can gain access to. This includes advertising, direct marketing, collateral, websites, industry events etc. 

Also, Starfish will utilize syndicated sources to read Competitive Activity/Spending to assess Amyris’ position in share of voice and
recommend directionally where Amyris should be. Please understand that these sources may not show real insight since Amyris’ category does not spend much in formal advertising, but Starfish will at least gain some idea for spending levels, SOV
(share of voice) and overall activity. 
 The Marketplace analysis is driven by a review of trade journals, industry reports and
any sources Amyris would recommend that will educate us on the state of the emerging business that Amyris plans on serving. 
  

	III.	Hypothesis Refinement 

 a. At the
conclusion of the Brand Dig, Starfish will explore positioning hypotheses that emerge from our findings. These will be refined into two or three possible brand strategies to be evaluated by the team. 

b. If needed, the final 1-2 strategic directions will be exposed to consumers via some form of qualitative research with the goal of
checking/refining our language and our thinking. 
 In the end, only Amyris can determine what kind of company Amyris want to be.
Our role will be to craft a positioning that brings that vision to life. 
  

	IV.	Touch Point Mapping 

Starfish’s Touch Point Mapping Process will examine thoroughly every one of Amyris’s potential brand interactions or touch
points whether these interactions are with the distribution channel or with the customer themselves. This analysis will identify ways in which to create a unique and meaningful brand experience. 

With this understanding, Starfish will present tactics at the highest level (i.e. initial thinking, not fully developed) that address the
ideal program. The final deliverable will include the completed map along with a thorough analysis of how the brand is perceived at each touch point. 
  

 2 

 Phase Two: 

Brand Development (Brand Strategy and Positioning) 

The output from Phase Two will consist of an actionable Brand Strategy and Positioning recommendation that includes: 

Brand Point of View: the driving passions and beliefs that exist within the Amyris organization 

Brand Idea: the brand intent boiled down to the simplest language possible (e.g. for Apple it’s “Simplicity”). 

Brand Mantra: a theme line or succinct rallying cry fit for public consumption. Likely will include a longer format description of the brand idea that
Starfish call a Brand Manifesto 
 The Proposition: How will the products/services affect people’s lives? 

The Support Points: The key reasons to believe the proposition. 

The Primary Target: Based in part on the outcome of the business analysis and agreement of the long-term growth plan 

Personality: the key attributes and characteristics of the brand that will inform the look, feel, tone and manner of all communications and activities

 A Creative Brief: to provide direction for development of all future brand expression 

Touch Point Map: that will provide an overview of the ideal touch point map that Starfish feel will create to improve the brand experience 

Brand Architecture and names: to provide specifics on corporate parent name, business names, product names, etc. 

Timing 
 Starfish believe that the scope
of work outlined in this proposal will require approximately 8 to 12 weeks to get us to the point where creative development can begin with core identity elements (logo, tagline, etc.). 

The following provides a rough timeline. A more detailed one will be built after our Kick-off meeting, but for now Starfish believe that following
guidelines will be give Amyris a sense of the time required for each of the phases: 
 Phase I — 5 to 7 weeks 

Phase II — 3 to 5 weeks 
 Please note that
creative development can begin at the end of phase 2 for any core brand identity and collateral elements. 
  

 3Amendment No. 1 to Stock Purchase Warrant - Starfish LLC

 Exhibit 4.11 

AMENDMENT NO. 1 TO STOCK PURCHASE WARRANT 

This Amendment No. 1 to Stock Purchase Warrant (this “Amendment”) is made and entered into as of
April 8, 2010 (the “Amendment Date”), by and among Starfish, LLC (“Starfish”) and Amyris Biotechnologies, Inc., a California corporation (the “Company”). 

RECITALS 

WHEREAS, the Company and Starfish are parties to that certain Stock Purchase Warrant dated March 6, 2008 (the
“Warrant”). 
 WHEREAS, the Company and Starfish desire to amend the Warrant. 

NOW, THEREFORE, in consideration of the matters described in the recitals above and the mutual promises, covenants and undertakings
contained herein, and intending to be legally bound hereby, the parties hereto agree as follows: 
 AMENDMENT 

1.      AMENDMENT TO SECTION 1(B) OF WARRANT. The definition of “Exercise Period” set
forth in Section 1(b) of the Warrant shall be deleted in its entirety and replaced with the following: 

“(b)    “Exercise Period” means the period commencing on the Warrant Issue Date and ending on the date
that is the earliest to occur of (x) 5:00 p.m. (prevailing local time at the principal executive office o the Company) on the fifth
(5th) anniversary of the Warrant Issue Date,
(y) a Change in Control, or (z) one (1) year from the effective date of an initial public offering of the Company’s securities. The settlement of the Warrant is to be made in Warrant Stock and, for the elimination of doubt, the
fact that the Warrant Stock delivered on exercise of the this Warrant is not registered under the Securities Act of 1933 will not in any way require you to settle the Warrant otherwise than in Warrant Stock, including, without limitation, that there
is no circumstance that would require the Company to net cash settle the Warrant.” 

2.      AMENDMENT TO WARRANT: NEW SECTION 3(f). A new Section 3(f) shall be added to the
Warrant to read in its entirety as follows: 
 “(f)    In case all the authorized Series B Preferred
Stock of the Company is converted, pursuant to the Articles of Incorporation, as amended from time to time, into Common Stock or other securities or property, or the Series B Preferred Stock otherwise ceases to exist, then, the Holder, upon exercise
of this Warrant at any time after such time (the “Conversion Date”), shall receive, in lieu of the number of shares of Warrant Stock that would have been issuable upon such exercise immediately prior to the Conversion Date
(the “Former Number of Shares of Warrant Stock”), the stock and other securities and property which the Holder would have been entitled to receive upon the Conversion Date if the Holder had exercised this Warrant with respect
to the Former Number of Shares of Warrant Stock immediately prior to the Conversion Date (all subject to further adjustment as provided in this Warrant).” 

 3.      NO OTHER AMENDMENTS. Except as expressly set
forth above, all of the terms and conditions of the Warrant remain in full force and effect. 

4.      GOVERNING LAW. This Amendment shall be governed by and construed under the internal laws of
the State of California as applied to agreements among California residents entered into and to be performed entirely within California, without reference to principles of conflict of laws or choice of laws. 

5.      COUNTERPARTS; FASCIMILE. This Amendment may be executed in two (2) or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment may be executed and delivered by facsimile, or by email in portable document format (.pdf) and delivery of the
signature page by such method will be deemed to have the same effect as if the original signature had been delivered to the other parties. 

[Remainder of page left blank] 

 IN WITNESS WHEREOF, each of the Company and Starfish has caused this Amendment
No. 1 to Stock Purchase Warrant to be executed by its duly authorized representative, each as of the Amendment Date. 
  

													
	AMYRIS BIOTECHNOLOGIES, INC.	 		 		 	    STARFISH, LLC
				
	 /s/ John Melo
	 		 		 	 /s/ David Kessler

							
	  By:	 	 John Melo
	 		 		 		 	  By:	 	 David Kessler

							
	  Its:	 	 Chief Executive Officer
	 		 		 		 	  Its:	 	 President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}]]